Skip to main content
Viewing from:
Department GEZ-LTA Erasmushogeschool
Intended for healthcare professionals
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
More
You are viewing from:
Department GEZ-LTA Erasmushogeschool
You are here
Home
Combinational immunotherapy
Email alerts
Combinational immunotherapy
Anti-PD-1 antibody significantly increases therapeutic efficacy of
Listeria monocytogenes (Lm)-
LLO immunotherapy
Mikayel
Mkrtichyan
,
Namju
Chong
,
Rasha
Abu Eid
,
Anu
Wallecha
,
Reshma
Singh
,
John
Rothman
,
Samir N
Khleif
Journal for ImmunoTherapy of Cancer
Dec 2013,
1
(1)
15;
DOI:
10.1186/2051-1426-1-15
Combination immunotherapy with α-CTLA-4 and α-PD-L1 antibody blockade prevents immune escape and leads to complete control of metastatic osteosarcoma
Danielle M
Lussier
,
John L
Johnson
,
Pooja
Hingorani
,
Joseph N
Blattman
Journal for ImmunoTherapy of Cancer
Dec 2015,
3
(1)
21;
DOI:
10.1186/s40425-015-0067-z
Special collections
COVID-19
(46)
Editor's choice
JITC
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Aging and diversity, equity, and inclusion (DEI) with regard to cancer immunotherapy and understudied populations
Basic Tumor Immunology
(620)
Cancer Immunotherapy in Understudied Populations
(5)
Case Reports
(192)
Clinical Trials Monitor
(17)
Clinical/Translational Cancer Immunotherapy
(1073)
Commentary/Editorials
(190)
Computational I-O
(6)
COVID-19 and Cancer Immunotherapy
(10)
Emerging Immunotherapeutic Agents
(5)
Guidelines and Consensus Statements
(61)
Guidelines and Consensus Statements
(52)
Imaging and Immunotherapy
(9)
Immune Cell Therapies and Immune Cell Engineering
(302)
Immune Checkpoints - Beyond PD-1
(8)
Immune Checkpoints Beyond PD-1 Series
(8)
Immune Monitoring Technology Primers
(12)
Immunotherapy Biomarkers
(510)
Liquid Biopsies
(8)
Microbial-Based Cancer Immunotherapy
(4)
Oncolytic and Local Immunotherapy
(172)
Reviews
(262)
SITC 40th Anniversary: I-O Progress and Potential
(7)
The Next Wave of Immuno-oncology: A Roadmap from the Society for Immunotherapy of Cancer (SITC)
(1)
Open access
(6905)
Press releases
(6)
